Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PDE2A | O00408 | 1/20 | 0.43 |
| ▸ | TLR9 | Q9NR96 | 9/20 | 0.42 |
| ▸ | TLR7 | Q9NYK1 | 9/20 | 0.42 |
| ▸ | TLR8 | Q9NR97 | 8/20 | 0.42 |
| ▸ | IDO1 | P14902 | 1/20 | 0.42 |
| ▸ | UHRF1 | Q96T88 | 1/20 | 0.41 |
| ▸ | USP30 | Q70CQ3 | 1/20 | 0.38 |
| ▸ | PIK3CD | O00329 | 1/20 | 0.38 |
| ▸ | PIK3CA | P42336 | 1/20 | 0.38 |
| ▸ | HTR1D | P28221 | 1/20 | 0.36 |
| ▸ | CASP3 | P42574 | 1/20 | 0.36 |
| ▸ | CDK9 | P50750 | 1/20 | 0.36 |
| ▸ | CASP7 | P55210 | 1/20 | 0.36 |
| ▸ | IKBKE | Q14164 | 1/20 | 0.35 |
| ▸ | TBK1 | Q9UHD2 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL9277352 | 0.87 | IDO1 (0.50) | TLR9TLR7TLR8IDO1UHRF1 | |
| SCHEMBL12093732 | 0.83 | IDO1 (0.45) | TLR9TLR7TLR8IDO1UHRF1 | |
| SCHEMBL12093743 | 0.83 | IDO1 (0.45) | TLR9TLR7TLR8IDO1UHRF1 | |
| Cyanide SCHEMBL27912025 | 0.81 | IDO1 (0.47) | TLR9TLR7TLR8IDO1UHRF1 | |
| SCHEMBL22402327 | 0.81 | IDO1 (0.44) | TLR9TLR7TLR8IDO1UHRF1 | |
| SCHEMBL11390639 | 0.81 | PIK3CD (0.42) | TLR9TLR7TLR8PIK3CDPIK3CA | |
| SCHEMBL5584522 | 0.80 | IDO1 (0.43) | TLR9TLR7TLR8IDO1UHRF1 | |
| SCHEMBL29210003 | 0.79 | TLR9 (0.46) | TLR9TLR7TLR8CASP3CDK9 | |
| SCHEMBL21213950 | 0.79 | PDE10A (0.40) | TLR9TLR7TLR8IDO1UHRF1 | |
| SCHEMBL23660437 | 0.79 | IDO1 (0.48) | TLR9TLR7TLR8IDO1UHRF1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20200339530-A1 | UREA DERIVATIVES AS INHIBITORS OF ASK1 | HEPAGENE THERAPEUTICS, INC. (VG) | 2020-10-29 | — | — | US | disclosed |
| US-20160303110-A1 | METHODS OF TREATING ABNORMAL MUSCULAR ACTIVITY | AUSPEX PHARMACEUTICALS, INC. (US) | 2016-10-20 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20160303110-A1 | METHODS OF TREATING ABNORMAL MUSCULAR ACTIVITY | PYGM, TNNC1, MUSK | PDE2A 47/4885TLR9 4522/4885TLR7 4136/4885 |
| US-20200339530-A1 | UREA DERIVATIVES AS INHIBITORS OF ASK1 | ATF1, ERN1, MAP3K1 | PDE2A 1636/4885TLR9 2714/4885TLR7 2820/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.